Acute effects of 2C-B compared to MDMA and psilocybin in healthy subjects
Résumé de l'étude
We investigate the altered states of consciousness induced by 2C-B, MDMA, and psilocybin. As part of the study, you will receive 3 x 2C-B at different dosages (10 mg, 20 mg, and 30 mg), 1 x MDMA (125 mg), 1 x psilocybin (25 mg), and 1 x placebo, with at least 10 days between each. Neither you nor your caregiver will know when you will receive which substance or placebo (“double-blind”). The order of substance administration is randomly determined. Thus, all participants receive all substances, just in a different order. During the study days, we will assess the subjective effect on the psyche using various questionnaires. Additionally, we will repeatedly measure pulse, blood pressure, and body temperature. To investigate the concentration profile of the substances in the blood, blood samples will be taken from you at various time points after substance administration. For this purpose, an intravenous catheter will be placed in your forearm, preferably in the elbow crease, each morning of the study days. The measurements (consisting of blood sampling, blood pressure and pulse measurements, as well as questionnaires) will be conducted in the first half of the day every half hour and in the second half of the day every hour. Between measurements, you will have time to read or listen to music. Throughout the study day, you will be supported by a trained and competent study team member who has extensive experience in handling psychoactive substances.
(BASEC)
Intervention étudiée
As part of the study, you will receive 3x 2C-B (10 mg, 20 mg, 30 mg), 1x MDMA (125 mg), 1x psilocybin (25 mg), and 1x placebo with at least 10 days between each.
(BASEC)
Maladie en cours d'investigation
Healthy subjects
(BASEC)
- Physically and mentally healthy - Aged between 25 and 65 years - BMI between 18 and 29 kg/m2 (BASEC)
Critères d'exclusion
- Excessive substance use (including medications, nicotine, and alcohol) - Pregnancy / Breastfeeding - Recent participation in another clinical study (BASEC)
Lieu de l’étude
Bâle
(BASEC)
Sponsor
Prof. Dr. med. Matthias E. Liechti
(BASEC)
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
Matthias Liechti
061 328 68 68
matthias.liechti@clutterusb.chDivision of Clinical Pharmacology and Toxicology - University Hospital of Basel
(BASEC)
Informations générales
University Hospital, Basel, Switzerland,
61 328 68 68;61 556 54 22
matthias.liechti@clutterusb.ch(ICTRP)
Informations générales
University Hospital, Basel, Switzerland
(ICTRP)
Informations scientifiques
University Hospital, Basel, Switzerland,
61 328 68 68;61 556 54 22
matthias.liechti@clutterusb.ch(ICTRP)
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Ethikkommission Nordwest- und Zentralschweiz EKNZ
(BASEC)
Date d'approbation du comité d'éthique
21.04.2022
(BASEC)
Identifiant de l'essai ICTRP
NCT05523401 (ICTRP)
Titre officiel (approuvé par le comité d'éthique)
Acute effects of 10, 20 and 30 mg 2C-B compared with 125 mg MDMA and 25 mg psilocybin in healthy subjects (BASEC)
Titre académique
Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects (ICTRP)
Titre public
Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects (ICTRP)
Maladie en cours d'investigation
Healthy (ICTRP)
Intervention étudiée
Drug: 4-bromo-2,5-dimethoxyphenethylamine (10 mg)Drug: 4-bromo-2,5-dimethoxyphenethylamine (20 mg)Drug: 4-bromo-2,5-dimethoxyphenethylamine (30 mg)Drug: 3,4-methylenedioxymethamphetamineDrug: PsilocybinOther: Placebo (ICTRP)
Type d'essai
Interventional (ICTRP)
Plan de l'étude
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Basic Science. Masking: Triple (Participant, Care Provider, Investigator). (ICTRP)
Critères d'inclusion/exclusion
Inclusion Criteria:
- Age between 25 and 65 years.
- Sufficient understanding of the German language.
- Understanding the procedures and the risks that are associated with the study.
- Participants must be willing to adhere to the protocol and sign the consent form.
- Participants must be willing to refrain from taking illicit psychoactive substances
during the study.
- Participants must be willing to drink only alcohol-free liquids and no coffee, black
or green tea, or energy drink after midnight of the evening before the study
session, as well as during the study day.
- Participants must be willing not to drive a traffic vehicle or to operate machines
within 48 h after substance administration.
- Women of childbearing potential must have a negative pregnancy test at the beginning
of the study. Pregnancy tests are repeated before each study session.
- Women of childbearing potential must be willing to use double-barrier birth control.
- Body mass index between 18-29kg/m2
Exclusion Criteria:
- Chronic or acute medical condition, including a history of seizures.
- Current or previous major psychiatric disorder (e.g. psychotic disorders, mania /
hypomania, anxiety disorders).
- Psychotic or bipolar disorder in first-degree relatives, not including psychotic
disorders secondary to an apparent medical reason, e.g. brain injury, dementia, or
lesions of the brain.
- Hypertension (SBP>140/90 mmHg) or hypotension (SBP<85 mmHg)
- Ilicit substance use (with the exception of cannabis) more than 20 times or any time
within the previous two months
- Pregnant or nursing women.
- Participation in another clinical trial (currently or within the last 30 days).
- Use of medications that may interfere with the effects of the study medications (any
psychiatric medications and any medication with known to interact with the study
substances).
- Tobacco smoking (>10 cigarettes/day).
- Consumption of alcoholic drinks (>20 drinks / week).
- Body weigt < 45 kg. (ICTRP)
non disponible
Critères d'évaluation principaux et secondaires
Acute subjective effects I (ICTRP)
Acute subjective effects II;Acute subjective effects III;Autonomic effects I;Autonomic effects II;Autonomic effects III;Plasma levels of 2C-B, MDMA, and psilocybin;Plasma levels of oxytocin;Plasma levels of Brain-derived neurotropic factor (BDNF);Adverse effects;Urine Recovery;States of Consciousness Questionnaire;Spiritual Realms Questionnaire;Psychological Insight Questionnaire;NEO-Five-Factor-Inventory (NEO-FFI);Freiburger Personality Inventory (FPI-R);Saarbr�cker Personality Questionnaire (SPF);HEXACO personality inventory;Defense Style Questionnaire (DSQ-40) (ICTRP)
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
non disponible
Contacts supplémentaires
Matthias E Liechti, MD;Matthias E Liechti, MD;Denis Arikci, MD, matthias.liechti@usb.ch; denis.arikci@usb.ch, 61 328 68 68;61 556 54 22, University Hospital, Basel, Switzerland, (ICTRP)
ID secondaires
BASEC 2022-00355 (ICTRP)
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
https://clinicaltrials.gov/ct2/show/NCT05523401 (ICTRP)
Résultats de l'essai
Résumé des résultats
non disponible
Lien vers les résultats dans le registre primaire
non disponible